Schizophrenia  >>  Invega Sustenna (paliperidone palmitate extended-release 1-month injection)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
NCT01150448: A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Completed
1
212
US, Europe, RoW
Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
06/09
06/09
NCT01942382: A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Completed
1
76
Japan
Paliperidone palmitate, JNS010
Janssen Pharmaceutical K.K.
Schizophrenia
03/10
03/10

Download Options